


# Supplementary Materials for

## NRF2-dependent Placental Effects Vary By Sex and Dose following Gestational Exposure to Ultrafine Particles


Jonathan C. Behlen<sup>1</sup>, Carmen H. Lau<sup>2</sup>, Drew Pendleton<sup>1</sup>, Yixin Li<sup>3</sup>, Aline Rodrigues Hoffmann<sup>2</sup>, Michael C. Golding<sup>4</sup>, Renyi Zhang<sup>3,5</sup> and Natalie M. Johnson<sup>1,\*</sup>

\* Correspondence: nmjohnson@tamu.edu; Tel.: +1-979-436-9325

### Supplementary Figures and Captions



**Figure. S1.** (A) Individual dams shown by ID number for wildtype (WT) and *Nrf2*<sup>-/-</sup> pregnant mice with corresponding average daily PM mass concentrations  $\pm$  SD measured within chambers from GD 0.5 to 18.5. (B) Average maternal weight gain mean  $\pm$  SD across exposure groups. Groups include wildtype (WT) filtered air (FA) control (n= 6; black line with circle), WT low dose (LD) (n=6; blue line with square), WT high dose (HD) (n=5; red line with triangle), *Nrf2*<sup>-/-</sup> FA (n=3; black line with inverted triangle), *Nrf2*<sup>-/-</sup> LD (n=3; blue line with diamond), and *Nrf2*<sup>-/-</sup> HD (n=5; red line with circle). No significant differences were observed across groups. (C) Low dose (LD) PM size (black) and concentration (gray) distribution, indicating 0.071  $\mu\text{m}$  (71 nm) as the peak particle diameter. (D) High dose (HD) PM particle size (black) and concentration (gray) distribution, indicating 0.079  $\mu\text{m}$  (79 nm) as the peak particle diameter.



**Figure. S2.** Illustration indicating exposure timeline. Each dam had a one-week acclimation period to exposure system (without PM) before time-mating. Upon the presence of plug or vaginal cytology with sperm (termed GD 0.5), dams were randomized into an exposure group and exposed throughout gestation until GD 18.5. Created with BioRender.com.

## Supplementary Tables

**Table S1.** Primer Sequences used in qRT-PCR of extracted RNA from pooled GD 18.5 sex-separated placentas.

Target	Forward Primer	Reverse Primer	NCBI Accession Number	Product Size (bp)
<i>Nqo1</i>	TGGCCGAACACAAGAAGCTG	GCTACGAGCACTCTCTCAAACC	NM_008706	112
<i>Ahr</i>	TGTGCAGAATCCCACATCCG	AATCAAGCGTGCATTGGACTG	NM_013464	114
<i>Cyp1b1</i>	CAGTCTGGCGTTCGGTCAC	GCTGCGTTGGATCGAGGAA	NM_009994	197
<i>Il β1</i>	GCCACCTTTTGACAGTGATGAG	AAGGTCCACGGGAAAGACAC	NM_008361	219
<i>Il6</i>	TCGTGGAAATGAGAAAAGAGTTGTG	GGTACTCCAGAAGACCAGAGG	NM_031168	177
<i>Tnf α</i>	CCATGAGCACAGAAAGCATGATC	GCCATTGGGAACTTCTCATCC	NM_013693	203
<i>Tgfβ1</i>	CAAGGGCTACCATGCCAACT	GTACTGTGTGCCAGGCTCCAA	NM_011577	67
<i>Smad3</i>	CACGCAGAACGTGAACACC	GGCAGTAGATAACGTGAGGGA	NM_016769	101
<i>Hnf4α</i>	GGTTTAGCCGACAATGTGTGG	TCCCGCTCATTTTGGACAGC	NM_008261	115
<i>Nr1h4</i>	GCTTGATGTGCTACAAAAGCTG	CGTGGTGATGGTTGAATGTCC	NM_001163700	110
<i>Apoa1</i>	GCTCAAGAGCAACCCTACCTT	GCTTTCTCGCCAAGTGTCTTC	NM_009692	75
<i>ApoB</i>	AAGCACCTCCGAAAGTACGTG	CTCCAGCTCTACCTTACAGTTGA	NM_009693	111
<i>Gapdh</i>	TGTCAAGCTCATTCCTGGTATGACA	GAGTTGGGATAGGGCCTCTCTT	NM_001289726	148


**Table S2.** Levels of individual redox species

<b>Maternal Serum</b>						
	<b>WT FA</b>	<b><i>Nrf2</i><sup>-/-</sup> FA</b>	<b>WT LD</b>	<b><i>Nrf2</i><sup>-/-</sup> LD</b>	<b>WT HD</b>	<b><i>Nrf2</i><sup>-/-</sup> HD</b>
GSH	0.01 ± 0.03	0.58 ± 0.51	1.64 ± 1.87	1.14 ± 0.22	1.23 ± 1.78	1.25 ± 0.51
GSSG	0.73 ± 0.34	1.49 ± 1.30	1.68 ± 1.08	2.06 ± 0.46	4.92 ± 4.32	1.71 ± 0.77
Cys	0.33 ± 0.47	1.21 ± 1.07	0.70 ± 1.22	1.39 ± 0.56	<b>0.12 ± 0.15</b>	<b>1.81 ± 0.29**</b>
CySS	17.73 ± 9.63	15.55 ± 12.82	20.24 ± 8.91	25.47 ± 0.56	16.26 ± 2.64	17.64 ± 6.33
<b>Male Placenta</b>						
	<b>WT FA</b>	<b><i>Nrf2</i><sup>-/-</sup> FA</b>	<b>WT LD</b>	<b><i>Nrf2</i><sup>-/-</sup> LD</b>	<b>WT HD</b>	<b><i>Nrf2</i><sup>-/-</sup> HD</b>
GSH	2.39 ± 2.14	4.29 ± 3.70	<b>2.57 ± 1.22</b>	<b>10.22 ± 1.56**</b>	1.94 ± 0.17	4.13 ± 3.54
GSSG	1.02 ± 0.79	2.51 ± 1.45	<b>0.86 ± 0.34</b>	<b>4.68 ± 0.75**</b>	0.50 ± 0.13	1.91 ± 0.81
Cys	1.90 ± 1.28	1.78 ± 1.29	2.05 ± 1.26	5.00 ± 1.24	1.87 ± 0.29	2.53 ± 2.59
CySS	0.74 ± 9.63	0.49 ± 0.02	1.08 ± 0.25	0.51 ± 0.01	0.71 ± 0.08	0.36 ± 0.13
<b>Female Placenta</b>						
	<b>WT FA</b>	<b><i>Nrf2</i><sup>-/-</sup> FA</b>	<b>WT LD</b>	<b><i>Nrf2</i><sup>-/-</sup> LD</b>	<b>WT HD</b>	<b><i>Nrf2</i><sup>-/-</sup> HD</b>
GSH	2.33 ± 2.26	1.49 ± 1.04	3.68 ± 1.31	4.53 ± 2.69	3.13 ± 0.56	2.89 ± 4.53
GSSG	1.46 ± 0.99	1.36 ± 0.89	1.46 ± 0.40	2.77 ± 1.34	0.60 ± 0.30	1.39 ± 2.18
Cys	1.40 ± 1.60	0.60 ± 0.30	2.41 ± 1.73	1.63 ± 0.57	3.86 ± 0.61	1.35 ± 2.16
CySS	0.60 ± 0.42	0.47 ± 0.05	<b>1.18 ± 0.24</b>	<b>0.38 ± 0.02**</b>	0.76 ± 0.07	0.24 ± 0.14

Oxidative stress biomarker averages ± SD depicting glutathione (GSH), glutathione disulfide (GSSG), cysteine (Cys), and cystine (CySS), values in maternal serum and placenta homogenates across exposure groups and genotype. Sample sizes shown in figure 2. Data analyzed using one-way ANOVA with Tukey's multiple comparison test. (\*p<0.05; \*\*p<0.01).

## Supplementary Methods

Genotypes of homozygous wild-type and *Nrf2*-deficient mice were confirmed by PCR amplification of genomic DNA extracted from tail snips. PCR amplification was carried out using established methods (Itoh et al. 1997) by using three different primers, 5'-TGGACGGGACTATTGAAGGCTG-3' (sense for both genotypes), 5'-CGCCTTTTCAGTAGATGGAGG-3' (antisense for wild type), and 5'-GCGGATTGACCGTAATGGGATAGG-3' (antisense for LacZ). Conditions were as follows, step 1 95°C 180 sec, step 2 95°C 30 sec, step 3 70°C 30 sec, step 4 72°C 30 sec, repeat steps 2-4 for 35 total cycles, followed by step 5 72°C 120 sec. Wild-type and mutant PCR products detected at 200-300 bp and 400 bp, respectively.



## Reference:

Itoh, K., et al., *An Nrf2/Small Maf Heterodimer Mediates the Induction of Phase II Detoxifying Enzyme Genes through Antioxidant Response Elements*. Biochemical and Biophysical Research Communications, 1997. 236(2): p. 313-322.